阿帕替尼在恶性肿瘤治疗中的临床应用

doi:10.3760/cma.j.issn.1673-422X.2019.01.010

摘要/Abstract

摘要： 阿帕替尼是一种小分子的酪氨酸激酶抑制剂，其通过高度选择性地作用于血管内皮细胞生长因子受体-2强效抑制肿瘤血管生成。阿帕替尼还可以阻滞细胞周期和逆转耐药。临床研究表明阿帕替尼对多种恶性肿瘤有效，如胃癌、非小细胞肺癌、乳腺癌等，具有较好的客观有效率和生存获益，同时具有良好的安全性和耐受性。

关键词: 肿瘤, 新生血管化, 病理性, 阿帕替尼, 血管内皮细胞生长因子受体-2, 分子靶向治疗

Abstract: Apatinib is a kind of antiangiogenesis drug of small molecular tyrosine kinase inhibitor, which can strongly against tumor angiogenesis by inhibiting vascular endothelial growth factor receptor 2 with highly selectivity. Apatinib can block cell cycle and reverse drug resistance. Clinical studies have shown that Apatinib is effective for many malignant tumors, including non-small-cell lung cancer, breast cancer and gastric cancer, which has encouraging objective response rate and survival benefit. Apatinib also has good safety and tolerance.

Key words: Neoplasms, Neovascularization, pathologic, Apatinib, Vascular endothelial growth factor receptor-2, Molecular targeted therapy

黄海,毕锋. 阿帕替尼在恶性肿瘤治疗中的临床应用[J]. 国际肿瘤学杂志, 2019, 46(1): 45-48.

Huang Hai, Bi Feng. Clinical application of Apatinib in the treatment of malignancies[J]. Journal of International Oncology, 2019, 46(1): 45-48.

参考文献

［1］ Roviello G, Ravelli A, Polom K, et al. Apatinib: a novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer［J］. Cancer Lett, 2016, 372(2): 187-191. DOI: 10.1016/j.canlet.2016.01.014. ［2］秦叔逵, 李进. 阿帕替尼治疗胃癌的临床应用专家共识［J］. 临床肿瘤学杂志, 2015, 20(9): 841-847. ［3］ Scott AJ, Messersmith WA, Jimeno A. Apatinib: a promising oral antiangiogenic agent in the treatment of multiple solid tumors［J］. Drugs Today (Barc), 2015, 51(4): 223-229. DOI: 10.1358/dot.2015.51.4.2320599. ［4］ Pinto MP, Owen GI, Retamal I, et al. Angiogenesis inhibitors in early development for gastric cancer［J］. Expert Opin Investig Drugs, 2017, 26(9): 1007-1017. DOI: 10.1080/13543784.2017.1361926. ［5］ Siemann DW, Chaplin DJ, Horsman MR. Realizing the potential of vascular targeted therapy: the rationale for combining vascular disrupting agents and antiangiogenic agents to treat cancer［J］. Cancer Invest, 2017, 35(8): 519534. DOI: 10.1080/07357907.2017.1364745. ［6］ Karasic TB, Rosen MA, O′Dwyer PJ. Antiangiogenic tyrosine kinase inhibitors in colorectal cancer: is there a path to making them more effective?［J］. Cancer Chemother Pharmacol, 2017, 80(4): 661-671. DOI: 10.1007/s00280-017-3389-3. ［7］ Zhang H. Apatinib for molecular targeted therapy in tumor［J］. Drug Des Devel Ther, 2015, 9: 6075-6081. DOI: 10.2147/DDDT.S97235. ［8］ Lee SH, Jeong D, Han YS, et al. Pivotal role of vascular endothelial growth factor pathway in tumor angiogenesis［J］. Ann Surg Treat Res, 2015, 89(1): 1-8. DOI: 10.4174/astr.2015.89.1.1. ［9］殷亮, 王荩, 黄凤昌, 等. 甲磺酸阿帕替尼对结肠癌HCT116细胞增殖的抑制作用及其机制［J］. 南方医科大学学报, 2017, 37(3): 367-372. DOI: 10.3969/j.issn.1673-4254.2017.03.15. ［10］ Rahimi N. Vascular endothelial growth factor receptors: molecular mechanisms of activation and therapeutic potentials［J］. Exp Eye Res, 2006, 83(5): 1005-1016. DOI: 10.1016/j.exer.2006.03.019 ［11］李彤, 翟二涛, 许丽霞, 等. 阿帕替尼通过阻断VEGF通路增强胃癌放疗疗效［J］. 中国病理生理杂志, 2017, 33(5): 776-781. DOI: 10.3969/j.issn.1000-4718.2017.05.002. ［12］ Mi YJ, Liang YJ, Huang HB, et al. Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATPbinding cassette transporters［J］. Cancer Res, 2010, 70(20): 7981-7991. DOI: 10.1158/0008-5472.CAN-10-0111 ［13］ Tong XZ, Wang F, Liang S, et al. Apatinib (YN968D1) enhances the efficacy of conventional chemotherapeutical drugs in side population cells and ABCB1overexpressing leukemia cells［J］. Biochem Pharmacol, 2012, 83(5): 586-597. DOI: 10.1016/j.bcp.2011.12.007. ［14］ Li J, Zhao X, Chen L, et al. Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor2 inhibitor YN968D1 in patients with advanced malignancies［J］. BMC Cancer, 2010, 10: 529. DOI: 10.1186/1471-2407-10-529. ［15］ Li J, Qin S, Xu J, et al. Apatinib for chemotherapyrefractory advanced metastatic gastric cancer: results from a randomized, placebocontrolled, parallelarm, phase Ⅱ trial［J］. J Clin Oncol, 2013, 31(26): 3219-3225. DOI: 10.1200/JCO.2013.48.8585. ［16］ Li J, Qin S, Xu J, et al. Randomized, doubleblind, placebocontrolled phase Ⅲ trial of apatinib in patients with chemotherapyrefractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction［J］. J Clin Oncol, 2016, 34(13): 1448-1454. DOI: 10.1200/JCO.2015.63.5995. ［17］ Geng R, Li J. Apatinib for the treatment of gastric cancer［J］. Expert Opin Pharmacother, 2015, 16(1): 117-122. DOI: 10.1517/14656566.2015.981526. ［18］ Li F, Zhu T, Cao B, et al. Apatinib enhances antitumour activity of EGFRTKIs in nonsmall cell lung cancer with EGFRTKI resistance［J］. Eur J Cancer, 2017, 84: 184-192. DOI: 10.1016/j.ejca.2017.07.037. ［19］ Hu X, Zhang J, Xu B, et al. Multicenter phase Ⅱ study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triplenegative breast cancer［J］. Int J Cancer, 2014, 135(8): 1961-1969. DOI: 10.1002/ijc.28829. ［20］ Hu X, Cao J, Hu W, et al. Multicenter phase Ⅱ study of apatinib in nontriplenegative metastatic breast cancer［J］. BMC Cancer, 2014, 14: 820. DOI: 10.1186/1471-2407-14820. ［21］ Fan M, Zhang J, Wang Z, et al. Phosphorylated VEGFR2 and hypertension: potential biomarkers to indicate VEGFdependency of advanced breast cancer in antiangiogenic therapy［J］. Breast Cancer Res Treat, 2014, 143(1): 141-151. DOI: 10.1007/s10549-013-2793-6. ［22］ Qin SK. Apatinib in Chinese patients with advanced hepatocellular carcinoma: a phase Ⅱ randomized, openlabel trial［J］. J Clin Oncol, 2014, 32(15 Suppl): 4019. DOI: 10.1200/jco.2014.32.15_suppl.4019. ［23］ Yu WC, Zhang KZ, Chen SG, et al. Efficacy and safety of apatinib in patients with intermediate/advanced hepatocellular carcinoma: a prospective observation study［J］. Medicine (Baltimore), 2018, 97(3): e9704. DOI: 10.1097/MD.0000000000009704. ［24］ Lu W, Jin XL, Yang C, et al. Comparison of efficacy between TACE combined with apatinib and TACE alone in the treatment of intermediate and advanced hepatocellular carcinoma: a singlecenter randomized controlled trial［J］. Cancer Biol Ther, 2017, 18(6): 433-438. DOI: 10.1080/15384047.2017.1323589. ［25］ Li F, Liao Z, Zhao J, et al. Efficacy and safety of apatinib in stage Ⅳ sarcomas: experience of a major sarcoma center in China［J］. Oncotarget, 2017, 8(38): 64471-64480. DOI: 10.18632/oncotarget.16293. ［26］ Zhu B, Li J, Xie Q, et al. Efficacy and safety of apatinib monotherapy in advanced bone and soft tissue sarcoma: an observational study［J］. Cancer Biol Ther, 2018, 19(3): 198-204. DOI: 10.1080/15384047.2017.1416275. ［27］ Liu K, Ren T, Huang Y, et al. Apatinib promotes autophagy and apoptosis through VEGFR2/STAT3/BCL2 signaling in osteosarcoma［J］. Cell Death Dis, 2017, 8(8): e3015. DOI: 10.1038/cddis.2017.422. ［28］ Zheng B, Ren T, Huang Y, et al. Apatinib inhibits migration and invasion as well as PDL1 expression in osteosarcoma by targeting STAT3［J］. Biochem Biophys Res Commun, 2018, 495(2): 1695-1701. DOI: 10.1016/j.bbrc.2017.12.032. ［29］ Li J, Wang L. Efficacy and safety of apatinib treatment for advanced esophageal squamous cell carcinoma［J］. Onco Targets Ther, 2017, 10: 3965-3969. DOI: 10.2147/OTT.S132756. ［30］ Liang L, Wang L, Zhu P, et al. A pilot study of apatinib as thirdline treatment in patients with heavily treated metastatic colorectal cancer［J］. Clin Colorectal Cancer, 2018, 17(3): e443e449. DOI: 10.1016/j.clcc.2018.02.011. ［31］林岩松, 王宸, 李慧, 等. 甲磺酸阿帕替尼治疗进展性碘难治性甲状腺癌的短期疗效及安全性初步报告［J］. 中国癌症杂志, 2016, 26(9): 721-726. DOI: 10.19401/j.cnki.1007-3639.2016.09.001. ［32］ Zhang M, Tian Z, Sun Y. Successful treatment of ovarian cancer with apatinib combined with chemotherapy: a case report［J］. Medicine (Baltimore), 2017, 96(45): e8570. DOI: 10.1097/MD.0000000000008570. ［33］Li CM, Liu ZC, Bao YT, et al. Extraordinary response of metastatic pancreatic cancer to apatinib after failed chemotherapy: a case report and literature review［J］. World J Gastroenterol, 2017, 23(41): 7478-7488. DOI: 10.3748/wjg.v23.i41.7478. ［34］Ji G, Hong L, Yang P. Successful treatment of advanced malignant fibrous histiocytoma of the right forearm with apatinib: a case report［J］. Onco Targets Ther, 2016, 9: 643-647. DOI: 10.2147/OTT.S96133. ［35］ Bi J, Liu H, Huang Y. The effect of apatinib in the treatment of metastatic renal cell carcinoma: a case report and review of the literature［J］. Int Med Case Rep J, 2017, 10: 223-227. DOI: 10.2147/IMCRJ.S137484 ［36］Zhang H, Chen F, Wang Z, et al. Successful treatment with apatinib for refractory recurrent malignant gliomas: a case series［J］. Onco Targets Ther, 2017, 10: 837-845. DOI: 10.2147/OTT.S119129. ［37］Luo C, Shen J, Ying J, et al. Case report of a KITmutated melanoma patient with an excellent response to apatinib and temozolomide combination therapy［J］. Onco Targets Ther, 2017, 10: 4553-4557. DOI: 10.2147/OTT.S146409. ［38］Li XF, Tan YN, Cao Y, et al. A case report of gastrointestinal hemorrhage and perforation during apatinib treatment of gastric cancer［J］. Medicine (Baltimore), 2015, 94(39): e1661. DOI: 10.1097/MD.0000000000001661.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.